您的位置: 首页 > 农业专利 > 详情页

USE OF CRISPR/CAS9 AS IN VIVO GENE THERAPY TO GENERATE TARGETED GENOMIC DISRUPTIONS IN GENES BEARING DOMINANT MUTATIONS FOR RETINITIS PIGMENTOSA
专利权人:
发明人:
Shaomei Wang,Benjamin Bakondi,Wenjian Lv,Bin Lu
申请号:
US15130846
公开号:
US20160324987A1
申请日:
2016.04.15
申请国别(地区):
US
年份:
2016
代理人:
摘要:
Described herein are methods and compositions for genomic editing. Clustered regularly interspaced short palindromic (CRISPR) allows for highly selective targeting and alteration of genetic loci. Here, the Inventors demonstrate CRISPR as capable of being used in living animals to prophylactically prevent a genetic disease from manifesting. Targeting and disruption of mutated rhodopsin gene prevents progression of retinitis pigmentosa in the retinal cells of a transgenic rat model. Such techniques allow for treatment methods in subjects with dominant genetic mutations, often associated with lack of a gene product, or a toxic gene product. The described technology effectively abrogates deleterious effects due to the presence of a mutated gene copy allowing the normal function of the wild-type protein to prevent cell and vision loss. The efficacy of these in vivo mechanisms are widely extensible to similar dominant negative gene mutations causing disease, or other types of genetic disease.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充